Demyelinating Autoimmune Diseases, CNS 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Demyelinating Autoimmune Diseases, CNS
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21
NCT02807285: Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

No Longer Available
N/A
US
Ocrelizumab, RO4964913
Genentech, Inc.
Multiple Sclerosis
 
 
RelSEP, NCT02883335: Lorraine Registry of Multiple Sclerosis

Recruiting
N/A
6000
Europe
Observational registry
Central Hospital, Nancy, France, Institut National de la Santé Et de la Recherche Médicale, France, University of Lorraine
Multiple Sclerosis
01/30
01/30

Download Options